Fate Therapeutics presented initial Phase 1 data for FT825 / ONO-8250, a HER2-targeting CAR T-cell therapy, showing a favorable safety profile in advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.